Effects of a lifestyle intervention in patients with Non-Alcoholic Fatty Liver Disease or Hepatitis C

Not Applicable

Completed

• Conditions: on-Alcoholic Fatty Liver Disease (NAFLD); Hepatitis C; Elevated liver enzymes; Overweight/Obesity; Metabolic Syndrome; Impaired glucose tolerance; Dyslipidemia; Non-Alcoholic Fatty Liver Disease (NAFLD); Metabolic and Endocrine - Metabolic disorders; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12616000992404
• Lead Sponsor: Professor Jacob George

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-07-28
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 180

Inclusion Criteria

Diagnosis of non-aldoholic fatty liver disease (NAFLD) or hepatitis C (and not receiving anti-viral therapy)
Males and females aged 18 years and over
Elevated ALT U/L) (>30 in males and >19 in females)

Exclusion Criteria

Alcohol intake >30g per day in males or >20g per day in females
Current injecting drug use or unstable drug habit
Liver cancer
Severe Depression (HADDS Score)
Cushing's Syndrome
Chronic Pancreatitis
Other liver diseases identified by appropriate tests including Hepatitis B (negative for hepatitis B surface antigen), autoimmune liver disease (antinuclear antibody, antismooth muscle antibody, anti-liver kidney microsomal antibody and antimitochondrial antibody), Wilson's disease (serum copper and ceruloplasmin levels), alpha-1 antitrypsin deficiency (alpha-1 antitrypsin deficiency (alpha-1 antitrypsin levels and alpha-1 antitrypsin genotype) and hemochromatosis (iron studies and genotyping for C268Y and H63D mutations).

Study & Design

• Study Type: Interventional
• Study Design: Not specified